Repligen Co. (RGEN) Shares Bought by Lord Abbett & CO. LLC

Lord Abbett & CO. LLC grew its holdings in Repligen Co. (NASDAQ:RGEN) by 286.3% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 733,291 shares of the biotechnology company’s stock after buying an additional 543,443 shares during the period. Lord Abbett & CO. LLC’s holdings in Repligen were worth $38,674,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors have also modified their holdings of the company. Fox Run Management L.L.C. acquired a new stake in shares of Repligen in the fourth quarter valued at about $456,000. Ardevora Asset Management LLP boosted its stake in Repligen by 471.7% during the fourth quarter. Ardevora Asset Management LLP now owns 612,077 shares of the biotechnology company’s stock worth $32,281,000 after buying an additional 505,020 shares during the period. Bank of New York Mellon Corp lifted its position in shares of Repligen by 3.4% during the third quarter. Bank of New York Mellon Corp now owns 516,025 shares of the biotechnology company’s stock worth $28,620,000 after purchasing an additional 17,176 shares in the last quarter. Arizona State Retirement System lifted its position in shares of Repligen by 6.3% during the fourth quarter. Arizona State Retirement System now owns 60,113 shares of the biotechnology company’s stock worth $3,170,000 after purchasing an additional 3,557 shares in the last quarter. Finally, Shell Asset Management Co. acquired a new stake in shares of Repligen during the third quarter worth about $466,000. 90.66% of the stock is owned by institutional investors and hedge funds.

A number of analysts have weighed in on the stock. BidaskClub cut shares of Repligen from a “buy” rating to a “hold” rating in a report on Wednesday, January 2nd. CL King upgraded shares of Repligen from a “neutral” rating to a “buy” rating in a research report on Monday, December 17th. They noted that the move was a valuation call. Finally, Zacks Investment Research upgraded shares of Repligen from a “hold” rating to a “buy” rating and set a $72.00 price objective on the stock in a research report on Wednesday, November 28th. Four analysts have rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus target price of $59.20.

Shares of RGEN opened at $59.17 on Friday. Repligen Co. has a 52-week low of $34.05 and a 52-week high of $70.50. The company has a market capitalization of $2.62 billion, a price-to-earnings ratio of 81.05, a price-to-earnings-growth ratio of 4.07 and a beta of 1.09.

Repligen (NASDAQ:RGEN) last issued its earnings results on Thursday, February 21st. The biotechnology company reported $0.21 earnings per share for the quarter, hitting the Thomson Reuters’ consensus estimate of $0.21. Repligen had a return on equity of 5.51% and a net margin of 8.56%. The firm had revenue of $51.90 million for the quarter, compared to analyst estimates of $50.27 million. During the same period last year, the company earned $0.20 earnings per share. The firm’s revenue for the quarter was up 24.8% on a year-over-year basis. Equities research analysts anticipate that Repligen Co. will post 0.83 earnings per share for the current year.

In other news, CFO Jon Snodgres sold 1,875 shares of the firm’s stock in a transaction dated Thursday, February 28th. The stock was sold at an average price of $58.88, for a total transaction of $110,400.00. Following the completion of the sale, the chief financial officer now directly owns 26,821 shares of the company’s stock, valued at approximately $1,579,220.48. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Anthony Hunt sold 13,000 shares of the stock in a transaction dated Tuesday, March 5th. The shares were sold at an average price of $58.50, for a total value of $760,500.00. Following the transaction, the chief executive officer now directly owns 229,657 shares in the company, valued at approximately $13,434,934.50. The disclosure for this sale can be found here. Insiders have sold 27,731 shares of company stock valued at $1,625,768 in the last ninety days. Company insiders own 1.40% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This piece of content was reported by WKRB News and is the property of of WKRB News. If you are accessing this piece of content on another site, it was illegally stolen and republished in violation of US and international copyright & trademark legislation. The legal version of this piece of content can be viewed at https://www.wkrb13.com/2019/03/15/repligen-co-rgen-shares-bought-by-lord-abbett-co-llc.html.

About Repligen

Repligen Corporation develops, manufactures, and sells products used to enhance the interconnected phases of the biological drug manufacturing process worldwide. It offers Protein A ligands to life sciences companies, which are the binding components of Protein A affinity resins; and growth factor products used to supplement cell culture media.

Read More: Average Daily Trade Volume – What You Need to Know

Want to see what other hedge funds are holding RGEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Repligen Co. (NASDAQ:RGEN).

Institutional Ownership by Quarter for Repligen (NASDAQ:RGEN)

Receive News & Ratings for Repligen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply